Abstract
The authors conducted a pilot randomized, double-blind, placebo- controlled clinical trial of the transdermal administration of selegiline in HIV+ patients to obtain preliminary data to assess its safety, tolerability, and impact on HIV-associated cognitive impairment. Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study.
Original language | English (US) |
---|---|
Pages (from-to) | 233-235 |
Number of pages | 3 |
Journal | Neurology |
Volume | 54 |
Issue number | 1 |
DOIs | |
State | Published - Jan 11 2000 |
Keywords
- Cognitive impairment
- HIV
- Selegiline
ASJC Scopus subject areas
- Clinical Neurology